

An AI-Enabled Clinical Trial Program's Impact on Patient Screening and Trial Enrollment in 2024

Samantha Mallahan, Chelsea Osterman, Danielle Skelly, Michelle Huang, Allison Madera, Sarah Salzman, Li-Pang Huang (Tempus AI, Inc.)

Ajeet Gajra (Hematology Oncology Associates of Central New York)

Ayed Ayed (Cancer Specialists of North Florida)

Jay Carlson (Mercy Health)

Ralph Hauke (Nebraska Cancer Specialists)

James Wade (Cancer Care Specialists of Illinois)

Syeda Bushra Ahesam (Cayuga Hematology Oncology Associates)

Sristee Niraula (Cayuga Medical Center)

Charles Redfern (Sharp HealthCare)

Jijun Liu (Illinois Cancer Care)


Janelle Meyer (Oregon Oncology Specialists)

Amol Rao (MemorialCare)

Benjamin Solomon (Avera Health)


Nihal Abdulla (Cancer and Blood Specialty Clinic)

Insufficient Accrual Into Oncology Trials Is a Well Established Complex Problem



Tempus AI is Data-Driven Precision Medicine

Tempus AI's mission is to bring the power of technology, data, and AI to doctors by building a leading precision medicine platform in the world - ultimately helping doctors make better decisions and help ensure patients live longer and healthier lives.



The Tempus AI TIME Program


- **Pre-screening** support via technical solutions and research nurse navigators
- Standardized **trial startup process** eases administrative burden
- **10-day Just-In-Time (JIT) activation** allows providers to open trials in response to patient need
- Program highlights:
 - **40,000+** patients identified for potential enrollment
 - **1,000+** clinical trials have been active
 - **~100** clinical sites representing **800+** locations
 - **~10% AMC**
 - **~90% Community**



**Testing with Tempus is not required to participate in the TIME program*

Patient Matching with AI Assistance

- 1 NGS & EMR data ingested into the TIME platform
- 2 Trial eligibility criteria coded into the platform & Natural Language Processing models deployed
- 3 Algorithmic matches identified
- 4 Tempus nurses confirm matches
- 5 High-quality matches sent to clinical site



Tempus AI TIME Program Clinical Trial Activation



Central IRB to streamline regulatory submissions



Standardized Clinical Trial Agreement for all sites, eliminating repetitive, prolonged negotiations



Rate Card with pre-negotiated costs

Just in Time


Occurs when a patient has been identified and needs to be immediately enrolled in the trial

Prospective

Patient(s) not yet identified but clinical site opens trial with expectations to enroll subjects


Just in TIME Trial Activation

Example Timeline of Patient Enrollment



Tempus AI TIME Program Patient Matching Data

- Continuously receives data
- Searches for new patients and others with updated medical data
- Searches occur as new trials are on-boarded and when trial criteria amendments occur



Tempus AI TIME Program Clinical Trial Activation Data

Activation Type	Total Activations	Median Activation Time
Just in Time	82	13 days
Prospective	104	33.5 days

*Median time from JIT activation to first consent for interventional trials was **4 days***


Tempus AI TIME Program Patients Screened & Consented Data

Screening and Enrollment

Nurse screened patients	35,912
Interventional matches	5,034
Interventional consents	225
Observational consents	348
Total consents	573

Interventional Consent Insights

Phase Breakdown




- 57% Phase 3
- 15% Phase 2
- 7% Phase 1, 5 consents from FIH trials

Most Common Cancer Types

- Breast
- NSCLC
- CRC
- Prostate
- Pancreatic

AI Facilitates Large-Scale Clinical Trial Enrollment



Authors & Acknowledgements

Samantha Mallahan, Chelsea Osterman, Danielle Skelly, Michelle Huang, Allison Madera, Sarah Salzman, Li-Pang Huang (Tempus AI, Inc.)

Ajeet Gajra (Hematology Oncology Associates of Central New York)

Ayed Ayed (Cancer Specialists of North Florida)

Jay Carlson (Mercy Health)

Ralph Hauke (Nebraska Cancer Specialists)

James Wade (Cancer Care Specialists of Illinois)

Syeda Bushra Ahesam (Cayuga Hematology Oncology Associates)

Sristee Niraula (Cayuga Medical Center)

Charles Redfern (Sharp HealthCare)

Jijun Liu (Illinois Cancer Care)

Janelle Meyer (Oregon Oncology Specialists)

Amol Rao (MemorialCare)

Benjamin Solomon (Avera Health)

Nihal Abdulla (Cancer and Blood Specialty Clinic)

We would like to acknowledge Amrita A. Iyer, PhD from the Tempus scientific writing team for helping put together this presentation.

How AI Helped Clinical Trials Find and Enroll Patients in 2024

What did this research tell us?

- The Tempus AI TIME program provides enhanced patient pre-screening and streamlines study start-up for oncology clinical trials, resulting in increased trial enrollment

Who does this research impact?

- The TIME program is a potential solution for academic and community-based research sites seeking to improve identification of patients that may be eligible for a clinical trial and wishing to leverage operational efficiencies to rapidly activate new studies

What does this mean for patients right now?

- The TIME program allows more patients to receive access to cutting-edge clinical trials closer to home